The boom of Viagra initially drove significant expansion in the medicinal sector, generating a understanding of easy returns. However, investing in companies primarily reliant on flagship drugs like the erectile dysfunction pill presents substantial risks. Exclusive rights expiration has led off-

The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for blockbuster treatments and impressive returns is cert